E1	Procedure:T1 Name:T83
E2	Or:T2 Arg:E1 Arg2:E3
E3	Procedure:T3 Name:T46
E4	Eq-Comparison:T4 Operator:T47 Value:T48
E5	Condition:T5 Name:T49 Minimum-Count:E4
E6	Eq-Comparison:T6 Temporal-Period:T50
E7	Procedure:T7 Temporality:E6
E8	Eq-Comparison:T8 Temporal-Period:T51
E10	Drug:T10 Name:T53 Temporality:E8
E11	Drug:T11 Name:T54
E12	Modifier:T12 Modifies:T53
E14	Drug:T14 Name:T55
E15	Drug:T15 Name:T56
E16	Modifier:T16 Modifies:T55
E18	Drug:T18 Name:T60
E19	Modifier:T19
E20	Or:T20 Arg:E18 Arg2:E21
E21	Drug:T21 Name:T62
E22	Drug:T22 Name:T63
E24	Study:T24
E25	Eq-Comparison:T25 Temporal-Period:T65
E26	Procedure:T26 Name:T66 Temporality:E25
E27	Procedure:T27 Name:T67
E28	Or:T28 Arg:E27 Arg2:E30
E29	Other:T29 Is-Other:E30
E30	Procedure:T30
E31	Eq-Comparison:T31 Temporal-Period:T69
E32	Condition:T32 Name:T70 Temporality:E31
E33	Or:T33 Arg:E32 Arg2:E35
E34	Eq-Comparison:T34 Temporal-Period:T71
E35	Condition:T35 Name:T72 Temporality:E34
E36	Risk:T36 Polarity:T73 Risk-For:E37
E37	Condition:T37 Name:T74
E38	Condition:T38 Name:T75 Temporality:E39
E39	Eq-Comparison:T39 Operator:T76 Value:T77 Temporal-Unit:T78
E40	Condition:T40 Name:T79
E41	Condition:T41 Name:T80
E42	Or:T42 Arg:E41 Arg2:E43
E43	Condition:T43 Name:T81
E44	Condition:T44 Name:T82
E46	Negation:T84 Negates:E7
E47	Modifier:T85 Modifies:E7
E48	Modifier:T86 Modifies:T49
E49	And:T87 Arg:E5 Arg2:E46
E9	Drug:T9 Name:T58
E13	Modifier:T13 Modifies:T62
E17	Condition:T17 Name:T68
E23	Modifier:T23 Modifies:T68
E50	Modifier:T52 Modifies:T75
E51	Modifier:T57 Modifies:T80
E52	Modifier:T59 Modifies:T79
E53	Modifier:T61 Modifies:T81
E54	And:T64 Arg:E43 Arg2:E44
T1	Procedure 59 55	histopathological
T2	Or 62 58	or
T3	Procedure 86 82	cytological examination
T4	Eq-Comparison 156 148	at least one
T5	Condition 173 165	lesion
T6	Eq-Comparison 232 223	received
T7	Procedure 248 239	treatment
T8	Eq-Comparison 310 297	previously received
T10	Drug 348 330	anti-programmed death receptor-1
T11	Drug 358 336	PD-1
T12	Modifier 369 346	antibody
T14	Drug 407 378	anti-programmed death ligand-1
T15	Drug 418 385	PD-L1
T16	Modifier 429 395	antibody
T18	Drug 478 434	PD-L2
T19	Modifier 489 444	antibody
T20	Or 492 447	or
T21	Drug 548 496	anti-cytotoxic T lymphocyte-associated antigen-4
T22	Drug 560 504	CTLA-4
T24	Study 640 581	study
T25	Eq-Comparison 681 620	previously received
T26	Procedure 690 629	TACE
T27	Procedure 716 654	radiofrequency ablation
T28	Or 720 658	and
T29	Other 726 664	other
T30	Procedure 750 688	treatments
T31	Eq-Comparison 782 718	history
T32	Condition 810 746	gastroesophageal varices
T33	Or 813 749	or
T34	Eq-Comparison 820 756	active
T35	Condition 834 770	cardia ulcers
T36	Risk 862 798	risk
T37	Condition 874 810	bleeding
T38	Condition 934 868	hemorrhage
T39	Eq-Comparison 949 882	within 1 year
T40	Condition 998 929	HCC
T41	Condition 1016 946	HCC
T42	Or 1019 949	or
T43	Condition 1044 974	cholangiocarcinoma
T44	Condition 1052 982	HCC
T46	Procedure-Name 86 82	cytological examination
T47	Eq-Operator 152 144	at least
T48	Eq-Value 156 148	one
T49	Condition-Name 173 165	lesion
T50	Eq-Temporal-Period 232 223	received
T51	Eq-Temporal-Period 310 297	previously received
T53	Drug-Name 348 330	anti-programmed death receptor-1
T54	Drug-Name 358 336	PD-1
T55	Drug-Name 407 378	anti-programmed death ligand-1
T56	Drug-Name 418 385	PD-L1
T58	Drug-Name 467 427	anti-programmed death ligand-2
T60	Drug-Name 478 434	PD-L2
T62	Drug-Name 548 496	anti-cytotoxic T lymphocyte-associated antigen-4
T63	Drug-Name 560 504	CTLA-4
T65	Eq-Temporal-Period 681 620	previously received
T66	Procedure-Name 690 629	TACE
T67	Procedure-Name 716 654	radiofrequency ablation
T68	Condition-Name 739 677	cancer
T69	Eq-Temporal-Period 782 718	history
T70	Condition-Name 810 746	gastroesophageal varices
T71	Eq-Temporal-Period 820 756	active
T72	Condition-Name 834 770	cardia ulcers
T73	Polarity 857 793	high
T74	Condition-Name 874 810	bleeding
T75	Condition-Name 934 868	hemorrhage
T76	Eq-Operator 941 875	within
T77	Eq-Value 944 877	1
T78	Eq-Temporal-Unit 949 882	year
T79	Condition-Name 998 929	HCC
T80	Condition-Name 1016 946	HCC
T81	Condition-Name 1044 974	cholangiocarcinoma
T82	Condition-Name 1052 982	HCC
T83	Procedure-Name 59 55	histopathological
T84	Negation 223 214	not
T85	Modifier 238 229	local
T86	Modifier 166 158	evaluable
T87	And 215 206	and
T9	Drug 467 427	anti-programmed death ligand-2
T13	Modifier 573 516	antibodies
T17	Condition 739 677	cancer
T23	Modifier 732 670	liver
T52	Modifier 923 857	upper gastrointestinal
T57	Modifier 1012 942	sarcomatoid
T59	Modifier 994 925	fibrous layer
T61	Modifier 1025 955	mixed
T64	And 1048 978	and
A1	Eq-Operator-Value T47 GTEQ
A2	Eq-Temporal-Period-Value T50 past
A3	Eq-Temporal-Period-Value T51 past
A9	Eq-Temporal-Period-Value T65 past
A10	Eq-Temporal-Period-Value T69 past
A11	Eq-Temporal-Period-Value T71 present
A12	Polarity-Value T73 high
A13	Eq-Operator-Value T76 LTEQ
A14	Eq-Temporal-Unit-Value T78 year
R1	Abbrev-Of Arg1:E11 Arg2:E10
R2	Abbrev-Of Arg1:E15 Arg2:E14
R3	Abbrev-Of Arg1:E18 Arg2:E9
R4	Abbrev-Of Arg1:E19 Arg2:E9
R5	Abbrev-Of Arg1:E22 Arg2:E21
R6	Treatment-For Arg1:E30 Arg2:E17
R7	Caused-By Arg1:E36 Arg2:E35